| From: chowder | 5/6/2021 4:23:52 PM | | | | | | Square EPS beats by $0.25, beats on revenue
May 06, 2021 4:13 PM ET Square, Inc. (SQ) By: Gaurav Batavia, SA News Editor 8 Comments
Square (NYSE: SQ): Q1 Non-GAAP EPS of $0.41 beats by $0.25; GAAP EPS of $0.08 beats by $0.14.
Revenue of $5.06B (+266.7% Y/Y) beats by $1.73B.In the first quarter of 2021, mid-market Seller GPV increased 43% year over year, more than 2x the growth of total Seller GPV.
Okay, now we'll see what sort of follow through we have. It was down 3.5% at the time of my comment, went down to 7% later in the session. Let's see where it opens tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: chowder who wrote (290) | 5/6/2021 5:12:21 PM | | From: inspbudget | | | | The general mood of growth stocks and the NASDAQ overall has been ugly the past couple weeks.
I hope that the Stock Price will improve, but looking at after hours action, would not be altogether surprised if it drops tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Frank Sully | 5/6/2021 11:18:35 PM | | | | | | Global CRISPR and CAS Gene Market to Surpass US$ 3,494.4 Million by 2027, Says Coherent Market Insights (CMI)
Wed, May 5, 2021, 10:00 AM
According to Coherent Market Insights, the global CRISPR and CAS gene market is estimated to be valued at US$ 830.7 million in 2020 and is expected to exhibit a CAGR of 22.8% during the forecast period (2020-2027).
Key Trends and Analysis of the Global CRISPR and CAS Gene Market:
Key trends in the market include increasing research and development activities, product launches, inorganic activities such as collaborations, and others.
Key players are focusing on increasing research and development for new treatments for genetic disorders, which is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, in June 2019, GlaxoSmithKline Plc partnered with gene-editing pioneers based at the University of California (UC) to establish a new laboratory that aims to speed up discovery of new treatments by exploring how gene mutations cause disease, and developing new CRISPR-based technologies.
Market players are indulged in launching new kits, which is expected to drive growth of the market over the forecast period. For instance, in June 2019, Synthego, a global genome engineering solutions company, announced the launch of the Gene Knockout Kit v2. This is the only product that leverages a novel bioinformatics- powered multi-guide strategy to guarantee a gene knockout. The kit will accelerate research by saving scientists from multiple trial-and-error cycles in optimizing their CRISPR experiment.
Various biotechnology and pharmaceutical companies are focusing on collaborations to conduct research and development for treatment of diseases such as cancer, AIDS, genetic diseases, and others, which is expected to drive growth of the market. For instance, in October 2019, CRISPR Therapeutics and Bayer announced plans for a joint venture between CRISPR Therapeutics and Bayer and Casebia Therapeutics would operate under the direct management of CRISPR Therapeutics. Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology, and autoimmune diseases.
Key Market Takeaways:
Increasing prevalence of genetic disorders such as Down’s syndrome, Sickle cell anemia, and Huntington’s disease worldwide is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, according to National Health Service (NHS) U.K., 2018 report, the highest rate of Huntington’s disease in the U.K. is 12 per 100,000 people.
Among all the regions, North America is expected to hold a dominant position in the global CRISPR and CAS gene market over the forecast period, owing to the increasing number of research studies regarding the CRISPR and CAS gene technology in the region. For instance, in 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR. Under the terms of the agreement, Juno had to pay Editas an initial payment of US$ 25 million, in which up to US$ 22 million will be used in research support for three programs over five years.
Competitive Landscape:
Key players operating in the global CRISPR and CAS gene market include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: 2hugo who wrote (294) | 5/7/2021 4:14:58 AM | | From: chowder | | | | >> Have you been adding/reducing to disruptive stocks besides crypto in any of your portfolios young/old folk?
Crypto only. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (289) | 5/7/2021 3:50:26 PM | | From: chowder | | | | I commented yesterday that SQ was set up as an example of how I like to front run an earnings report. At the time it was down 3.5%, dropped as low as 7% and is currently up today at 4% after a stellar earnings report.
I wish all purchases were this easy.
The catalyst was the PYPL earnings report and the positive reaction the market had to it. I assumed SQ would have similar results and they did not disappoint. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (279) | 5/8/2021 9:40:23 AM | | From: Cogito Ergo Sum | | | | | Well I have collision avoidance on my 2018 Coloarado.. but also lane divergence .. I got to tell you I am impressed .. even in snowy conditions it is pretty awesome.. I learned to drive in chitty QC weather.. have a good feel for where the road is in bad chit.. but this stuff works great.. it has been bang on even in snowy roads.. I do not know that the tech is .. guess I should check.. but it is great.. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: chowder | 5/8/2021 12:31:59 PM | | | | | | CRYPTO CURRENCY PORTFOLIO ... As of May 8, 2021 this is what my crypto asset portfolio consists of.
ASSET ..... % OF PORTFOLIO
Bitcoin (BTC) ... 26.5%
Ethereum (ETH) ... 21.3%
Marathon Digital Holdings (MARA) ... 15.8%
Litecoin (LTC) ... 8.8%
Algorand (ALGO) ... 6.4%
Cosmos (ATOM) ... 6.4%
Cardano (ADA) ... 5.7%
Aave (AAVE) ... 5.1%
Ren (REN) ... 3.9%
Compound (COMP) ... .06%
Stellar Lumens (XLM) ... .06%
Celo (CGLD) ... 0.6% Uma (UMA) ... 0.6%
The Graph (GRT) ... .01%
NuCypher (NU) ... .01%
Ampleforth Governance Token (FORTH) ... .01%
Bitcoin(BTC) ... Each Bitcoin is basically a computer file which is stored in a 'digital wallet' app on a smartphone or computer. People can send Bitcoins (or part of one) to your digital wallet, and you can send Bitcoins to other people. Every single transaction is recorded in a public list called the blockchain.
Ethereum (ETH) ... You can use Ether as a digital currency in financial transactions, as an investment or as a store of value. Ethereum is the blockchain network on which Ether is held and exchanged. As mentioned above, however, this network offers a variety of other functions outside of ETH.
Marathon Digital Holdings (MARA) ... Marathon is a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets.
Litecoin (LTC) ... Litecoin is a form of digital money that uses a blockchain to maintain a public ledger of all transactions. It is used to transfer funds between individuals or businesses without the need for an intermediary such as a bank or payment processing service.
Cosmos (ATOM) ... Cosmos is a dual-layer network that enables token, data, and asset exchanges between blockchains. Each chain on the network operates independently. Cosmos Hubs validate on-chain transactions and earn ATOM through staking. ATOM is the native cryptocurrency token of the Cosmos Network.
Cardano (ADA) ... Cardano is a proof-of-stake blockchain platform: the first to be founded on peer-reviewed research and developed through evidence-based methods. Any user, located anywhere in the world, can use ada as a secure exchange of value – without requiring a third party to mediate the exchange. Every transaction is permanently, securely, and transparently recorded on the Cardano blockchain.
Aave (AAVE) ... Aave is a decentralized non-custodial money market protocol. Depositors provide liquidity to the market to earn a passive income, while borrowers are able to borrow in an overcollateralized (perpetually) or under collateralized fashion.
Ren (REN) ... Ren is an Ethereum token that powers Ren's open protocol for transferring cryptocurrencies between blockchains. Ren aims to bring popular assets like Bitcoin and Zcash to blockchains including Ethereum, making it possible for these assets to participate in a multi-chain decentralized finance ecosystem.
Compound (COMP) ... Compound is a company that allows people to earn money on the crypto they save. The project is part of Ethereum and more broadly, DeFi. Users can also borrow crypto from Compound by putting up collateral above a threshold defined by the project.
Stella Lumens (XLM) ... Stellar Lumens, is an open source, decentralized protocol for digital currency to fiat money transfers which allows cross-border transactions between any pair of currencies.
Celo (CGLD) ... Celo is a cryptocurrency that acts as a utility and governance token for the Celo (CGLD) platform. Celo (CGLD) is designed to make it easy for anyone with a smartphone to send, receive, and store stablecoins running on Celo (CGLD) (for example, the Celo Dollar) without needing a crypto wallet.
Uma (UMA) ... UMA, short for universal market access, is a protocol built on Ethereum which allows users to create custom collateralized synthetic cryptocurrency tokens that can track the price of virtually anything.
The Graph (GRT) ... The Graph is an indexing protocol for querying networks like Ethereum and IPFS. Anyone can build and publish open APIs, called subgraphs, making data easily accessible.
NuCypher (NU) ... NuCypher is a data encryption and protection layer for Ethereum (and eventually other networks) and decentralized applications (dApps) that does not rely on a central service provider. ... Developers receive this encryption service via a network of NuCypher nodes in exchange for a fee (paid for in ETH).
Ampleforth Governance Token (FORTH) ... FORTH is the governance token for Ampleforth, an Ethereum protocol that automatically adjusts its native token supply. Learn how it works and earn free FORTH. Note: new customers must wait 24 hours and fulfill all eligibility criteria to earn FORTH. Supplies are limited. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
